Evaluation the frequency of factor V Leiden mutation in pregnant women with preeclampsia syndrome in an Iranian population

Iranian Journal of Reproductive Medicine

Volumn 10, Issue 1, 2012, Pages 59-66

  Karimi, Samieh ^a   Yavarian, Majid ^b   Azinfar, Azadeh ^a   Rajaei, Minoo ^a   Kootenaee, Maryam Azizi ^a  

^a HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Factor V leiden mutation; Iran; Obstetric complication; Preeclampsia

Indexed keywords

ADENINE; BLOOD CLOTTING FACTOR 5 LEIDEN; GENOMIC DNA; GUANINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; CASE CONTROL STUDY; CESAREAN SECTION; CONTROLLED STUDY; DNA EXTRACTION; ETHNIC GROUP; FEMALE; GENE MUTATION; GENETIC VARIABILITY; HUMAN; INCIDENCE; INTRAUTERINE GROWTH RETARDATION; IRANIAN; MAJOR CLINICAL STUDY; PATHOGENESIS; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANT WOMAN; PREMATURE LABOR; PREVALENCE; PROTEINURIA; RISK FACTOR;

EID: 83455162895     PISSN: 16806433     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Irminger-Finger I, Jastrow N, Irion O. Preeclampsia: A danger growing in disguise. Int J Biochem Cell Biol 2008; 40: 1979-1983.
2. Saadat M, Nejad SM, Habibi G, Sheikhvatan M. Maternal and neonatal outcomes in women with preeclampsia. Taiwan J Obstet Gynecol 2007; 46: 255-259.
3. Dildy GA, Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol 2007; 31: 135-141.
4. Bolte AC, van Geijn HP, Dekker GA. Management and monitoring of severe preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001; 96: 8-20.
5. Gaugler-Senden IP, Huijssoon AG, Visser W, Steegers EA, de Groot CJ. Maternal and perinatal outcome of preeclampsia with an onset before 24 weeks' gestation: Audit in a tertiary referral center. Eur J Obstet Gynecol Reprod Biol 2006; 128: 216-221.
6. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 2001; 97: 533-538.
7. Lachmeijer AM, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrímsson R. Searching for preeclampsia genes: The current position. Eur J Obstet Gynecol Reprod Biol 2002; 105: 94-113.
8. Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res 2010; 125: 119-123.
9. Paidas MJ, Ku D-HW, Langhoff-Roos J, Arkel YS. Inherited thrombophilias and adverse pregnancy outcome: Screening and management. Semin Perinatol 2005; 29: 150-163.
10. Hiltunen LM, Laivuori H, Rautanen A, Kaaja R, Kere J, Krusius T, et al. Blood group ab and factor V Leiden as risk factors for pre-eclampsia: A population-based nested case-control study. Thromb Res 2009; 124: 167-173.
11. Facchinetti F, Marozio L, Frusca T, Grandone E, Venturini P, Tiscia GL, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200: 41-45.
12. Howley HE, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005; 192: 694-708.
13. Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: The hordaland homocysteine study. QJM 2006; 99: 289-298.
14. Mtiraoui N, Borgi L, Hizem S, Nsiri B, Finan RR, Gris J-C, et al. Prevalence of antiphospholipid antibodies, factor V g1691a (Leiden) and prothrombin g20210a mutations in early and late recurrent pregnancy loss. Eur J Obstet Gynecol Reprod Biol 2005; 119: 164-170.
15. Hiltunen LM, Laivuori H, Rautanen A, Kaaja R, Kere J, Krusius T, et al. Factor V Leiden as risk factor for unexplained stillbirth- a population-based nested case-control study. Thromb Res 2010; 125: 505-510.
16. Glueck CJ, Gogenini S, Munjal J, Tracy T, Pranikoff J, Wang P. Factor V Leiden mutation: A treatable etiology for sporadic and recurrent pregnancy loss. Fertil Steril 2008; 89: 410-416.
17. Hussein AS, Darwish H, Shelbayeh K. Association between factor V Leiden mutation and poor pregnancy outcomes among palestinian women. Thromb Res 2010; 126: 78-82.
18. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM. Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185: 153-157.
19. Salomon O, Seligsohn U, Steinberg DM, Zalel Y, Lerner A, Rosenberg N, et al. The common prothrombotic factors in nulliparous women do not compromise blood flow in the feto-maternal circulation and are not associated with preeclampsia or intrauterine growth restriction. Am J Obstet Gynecol 2004; 191: 2002-2009.
20. Von Tempelhoff GF, Heilmann L, Spanuth E, Kunzmann E, Hommel G. Incidence of the factor V Leiden-mutation, coagulation inhibitor deficiency, and elevated antiphospholipid-antibodies in patients with preeclampsia or hellp-syndrome. Thromb Res 2000; 100: 363-365.
21. Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ, Peraud PJ, et al. Genetic susceptibility to preeclampsia: Roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine P-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184: 1211-1217.
22. Nath CA, Ananth CV, DeMarco C, Vintzileos AM, New Jersey-Placental Abruption Study Investigators. Low birthweight in relation to placental abruption and maternal thrombophilia status. Am J Obstet Gynecol 2008; 198: 291-295.
23. ACOG Committee on Obstetrics Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, january 2002. American college of obstetricians and gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75.
24. Lucotte G, Mercier G. Population genetics of factor V leiden in europe. Blood Cells Mol Dis 2001; 27: 362-367.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
26. Beauchamp NJ, Daly ME, Hampton KK, Cooper PC, Preston FE, Peake IR. High prevalence Prothrombin G20210A was reported to be more common of a mutation in the factor V gene within the UK population: relationship to activated protein C resistance and familial thrombosis. Br J Haematol 1994; 88: 219-222.
27. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210a, methylenetetrahydrofolate reductase 677t, and population genetics. Mol Genet Metab 2005; 86: 91-99.
28. Limdi NA, Beasley TM, Allison DB, Rivers CA, Acton RT. Racial differences in the prevalence of factor V Leiden mutation among patients on chronic warfarin therapy. Blood Cells Mol Dis 2006; 37: 100-106.
29. Kobashi G, Yamada H, Asano T, Nagano S, Hata A, Kishi R, et al. The factor V Leiden mutation is not a common cause of pregnancy-induced hypertension in japan. Semin Thromb Hemost 1999; 25: 487-489.
30. Rahimi Z, Vaisi-Raygani A, Mozafari H, Kharrazi H, Rezaei M, Nagel RL. Prevalence of factor V Leiden (G1691A) and prothrombin (G20210A) among Kurdish population from Western Iran. J Thromb Thrombolysis 2008; 25: 280-283.
31. Karimi M, Panahandeh Shahraki G, Yavarian M, Afrasiabi A, Dehbozorgian J, Bordbar M, et al. Frequency of factor V Leiden and Prothrombin Polymorphism in South of Iran. Iran J Med Sci 2009; 34: 137-140.
32. Dashti AA, Jadaon MM. Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals. Mol Biol Rep 2011; 38: 3623-3628.
33. Sadat Hosseini M, Gharehkhani P, Sadeghi M. Association of inherited thrombophilia and antiphospholipid syndrome with sever preeclampsia. Iran J Reprod Med 2007; 5: 183-186.
34. Dizon-Townson DS, Nelson LM, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-905.
35. Dávalos IP, Moran MC, Martínez-Abundis E, González-Ortiz M, Flores-Martínez SE, Machorro V, et al. Methylenetetrahydrofolate reductase c677t polymorphism and factor V Leiden variant in mexican women with preeclampsia/eclampsia. Blood Cells Mol Dis 2005; 35: 66-69.
36. Prasmusinto D, Skrablin S, Fimmers R, van der Ven K. Ethnic differences in the association of factor V Leiden mutation and the c677t methylenetetrahydrofolate reductase gene polymorphism with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2004; 112: 162-169.
37. Dudding T, Heron J, Thakkinstian A, Nurk E, Golding J, Pembrey M, et al. Factor V Leiden is associated with pre-eclampsia but not with fetal growth restriction: A genetic association study and meta-analysis. J Thromb Haemost 2008; 6: 1869-1875.
38. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: A meta-analysis. J Hypertens 2003; 21: 1221-1228.
39. Dalmáz CA, Santos KG, Botton MR, Tedoldi CL, Roisenberg I. Relationship between polymorphisms in thrombophilic genes and preeclampsia in a brazilian population. Blood Cells Mol Dis 2006; 37: 107-110.
40. Kahn SR, Platt R, McNamara H, Rozen R, Chen MF, Genest J, et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: The montreal preeclampsia study. Am J Obstet Gynecol 2009; 200: 151-159.
41. Zahed LF, Rayes RF, Mahfouz RA, Taher AT, Maarouf HH, Nassar AH. Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in lebanon. Am J Obstet Gynecol 2006; 195: 1114-1118.
42. Wang Y, Walli AK, Schulze A, Blessing F, Fraunberger P, Thaler C, et al. Heparin-mediated extracorporeal low density lipoprotein precipitation as a possible therapeutic approach in preeclampsia. Transfus and Apher Sci 2006; 35: 103-110.